Evidence map›Paper›PMID 26021757›Full record

ArticleScientific reports2015

The Cullin 4A/B-DDB1-Cereblon E3 Ubiquitin Ligase Complex Mediates the Degradation of CLC-1 Chloride Channels.

Yi-An Chen, Yi-Jheng Peng, Meng-Chun Hu, Jing-Jia Huang, Yun-Chia Chien, June-Tai Wu, Tsung-Yu Chen, Chih-Yung Tang

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Pin1 promotes human CaCell communication and signaling : CCS · 2024
    Article
  8. Article
  9. Article
  10. UDP-Glucose: A Cereblon-Dependent Glucokinase Protein Degrader.International journal of molecular sciences · 2022
    Article
  11. Article
  12. Review
  13. Cereblon: promise and challenges for combating human diseases.Pflugers Archiv : European journal of physiology · 2021
    Review
  14. Cereblon Regulates the Proteotoxicity of Tau by Tuning the Chaperone Activity of DNAJA1.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Skeletal muscle ClC-1 chloride channels in health and diseases.Pflugers Archiv : European journal of physiology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Yi-An ChenDepartment of Physiology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Yi-Jheng PengDepartment of Physiology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Meng-Chun HuDepartment of Physiology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Jing-Jia HuangDepartment of Physiology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Yun-Chia ChienDepartment of Physiology, College of Medicine, National Taiwan University, Taipei, Taiwan.
June-Tai WuInstitute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Tsung-Yu ChenNeuroscience Center, University of California, Davis, USA.
Chih-Yung Tang1] Department of Physiology, College of Medicine, National Taiwan University, Taipei, Taiwan [2] Graduate Institute of Brain and Mind Sciences, College of Medicine, National Taiwan University, Taipei, Taiwan.
National Taiwan University · TWUniversity of California, Davis · US

Funding

Molecular Physiology of CLC Chloride ChannelsR01GM065447 · NIGMS · UNIVERSITY OF CALIFORNIA DAVIS · PI CHEN, TSUNG-YU · 2003 to 2018
$3.9M
NIGMS NIH HHS R01 GM065447NIGMS NIH HHS R01GM065447
6 · The paper itself

Abstract

Voltage-gated CLC-1 chloride channels play a critical role in controlling the membrane excitability of skeletal muscles. Mutations in human CLC-1 channels have been linked to the hereditary muscle disorder myotonia congenita. We have previously demonstrated that disease-associated CLC-1 A531V mutant protein may fail to pass the endoplasmic reticulum quality control system and display enhanced protein degradation as well as defective membrane trafficking. Currently the molecular basis of protein degradation for CLC-1 channels is virtually unknown. Here we aim to identify the E3 ubiquitin ligase of CLC-1 channels. The protein abundance of CLC-1 was notably enhanced in the presence of MLN4924, a specific inhibitor of cullin-RING E3 ligases. Subsequent investigation with dominant-negative constructs against specific subtypes of cullin-RING E3 ligases suggested that CLC-1 seemed to serve as the substrate for cullin 4A (CUL4A) and 4B (CUL4B). Biochemical examinations further indicated that CUL4A/B, damage-specific DNA binding protein 1 (DDB1), and cereblon (CRBN) appeared to co-exist in the same protein complex with CLC-1. Moreover, suppression of CUL4A/B E3 ligase activity significantly enhanced the functional expression of the A531V mutant. Our data are consistent with the idea that the CUL4A/B-DDB1-CRBN complex catalyses the polyubiquitination and thus controls the degradation of CLC-1 channels.

Indexed as

Adaptor Proteins, Signal TransducingChloride ChannelsCullin ProteinsDNA-Binding ProteinsHumansMultiprotein ComplexesMuscle, SkeletalMutationMyotonia CongenitaPeptide HydrolasesProteolysisUbiquitin-Protein LigasesAdaptor Proteins, Signal TransducingChloride ChannelsCLC-1 channelCRBN protein, humanCUL4A protein, humanCUL4B protein, humanCullin ProteinsDDB1 protein, humanDNA-Binding ProteinsMultiprotein ComplexesPeptide HydrolasesUbiquitin-Protein Ligases

Identifiers

PMID26021757
PMCPMC4448132
OpenAlexW2272879411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.